Cannasouth Past Earnings Performance
Past criteria checks 0/6
Cannasouth's earnings have been declining at an average annual rate of -26%, while the Pharmaceuticals industry saw earnings growing at 41.5% annually. Revenues have been growing at an average rate of 11332.8% per year.
Key information
-26.0%
Earnings growth rate
29.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.6% |
| Revenue growth rate | 11,332.8% |
| Return on equity | -18.2% |
| Net Margin | -921.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Cannasouth makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -9 | 7 | 1 |
| 31 Dec 22 | 0 | -7 | 7 | 0 |
Quality Earnings: CBD is currently unprofitable.
Growing Profit Margin: CBD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CBD's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CBD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.4%).
Return on Equity
High ROE: CBD has a negative Return on Equity (-18.22%), as it is currently unprofitable.